Latest News
Moleculin Forges Additional Collaboration on Drug Candidate Targeting COVID-19
29 October 2020 - - US-based pharmaceutical company Moleculin Biotech, Inc., (NASDAQ: MBRX) has entered into an agreement with the University of Campinas in São Paulo, Brazil to further enable collaboration into its research on the a...
Data for Lilly's Bamlanivimab in COVID-19 Outpatients Published in New England Journal of Medicine
29 October 2020 - - The New England Journal of Medicine has published data from the monotherapy arms of BLAZE-1, a Phase 2 study assessing the efficacy and safety of US-based pharmaceutical company Eli Lilly and company's (NYSE: LLY) b...
First Patient Dosed in NIH ACTIV-5/Big Effect Trial Evaluating Lenzilumab for COVID-19
29 October 2020 - - The first patient has been dosed at the Emory University School of Medicine in Atlanta, Georgia as part of the in the ACTIV-5 "Big Effect Trial" (ACTIV-5/BET) evaluating lenzilumab with remdesivir, compared to placebo an...
Regeneron Says COVID-19 Outpatient Trial Prospectively Demonstrates that REGN-COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical Attention
29 October 2020 - - US-based biotechnology company Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has released positive, prospective results from an ongoing Phase 2/3 seamless trial in the COVID-19 outpatient setting showing its investigational antib...
COVID-19 Immune Response Study Could Lead to More Effective Treatments
29 October 2020 - - A COVID-19 immune response study has revealed new findings that suggest that treatments aimed at arresting the infection at the stage of moderate severity may be most effective, the US-based non-profit biomedical research organisa...